Provided by Tiger Trade Technology Pte. Ltd.

Ecopetrol SA

17.27
-0.2650-1.51%
Volume:690.12K
Turnover:11.88M
Market Cap:35.49B
PE:9.07
High:17.33
Open:17.23
Low:17.06
Close:17.53
52wk High:18.19
52wk Low:8.57
Shares:2.06B
Float Shares:237.00M
Volume Ratio:0.68
T/O Rate:0.29%
Dividend:0.99
Dividend Rate:5.74%
EPS(TTM):1.90
EPS(LYR):1.16
ROE:15.95%
ROA:7.31%
PB:1.73
PE(LYR):14.82

Loading ...

Moody’s downgrades Ecopetrol’s global credit rating to Ba2

TIPRANKS
·
May 07

Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference

GlobeNewswire
·
May 06

Royalty Pharma reports first quarter 2026 results

GlobeNewswire
·
May 06

UBS Sticks to Its Hold Rating for Ecopetrol SA (EC)

TIPRANKS
·
May 06

Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update

GlobeNewswire
·
May 06

Ecopetrol Is Maintained at Neutral by UBS

Dow Jones
·
May 06

Ecopetrol price target raised to $13.50 from $10 at UBS

TIPRANKS
·
May 05

UBS Adjusts Price Target on Ecopetrol to $13.50 From $10, Maintains Neutral Rating

MT Newswires Live
·
May 05

Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

GlobeNewswire
·
May 05

Earning Preview: Ecopetrol SA Q1 revenue is expected to decrease by 3.14%, and institutional views are cautious

Earnings Agent
·
May 05

Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society

GlobeNewswire
·
May 04

Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity

GlobeNewswire
·
May 01

Press Release: Ecopetrol Files Its Form 20-F for the Fiscal Year 2025 with the U.S. Securities and Exchange Commission

Dow Jones
·
May 01

Ecopetrol price target raised to $11 from $9.50 at JPMorgan

TIPRANKS
·
Apr 30

Press Release: Santhera Proposes Dr. Srishti Gupta as New Member of the Board of Directors

Dow Jones
·
Apr 30

X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union

GlobeNewswire
·
Apr 29

Regeneron Reports First Quarter 2026 Financial and Operating Results

GlobeNewswire
·
Apr 29

Creating a Sustainable Impact: Fosun International Releases 2025 ESG Report and Climate Information Disclosures Report

prnewswire
·
Apr 28

Solid Biosciences receives orphan drug designation for SGT-003 from EC

TIPRANKS
·
Apr 28

Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy

GlobeNewswire
·
Apr 28